|
BioScreening - organic compounds for screening
Medicinal Chemistry NewsInvitrogen Scientists Link microRNA Sequences to Cancer Using RNA Samples from BioServe - Carlsbad, Calif., and Beltsville, Md., May 7, 2008 – In research demonstrating that RNA previously thought to have no biological relevance may be of use for therapeutic and diagnostic targets, Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and BioServe, the leading provider of clinically annotated tissue samples [...]
Ono Enters into a New Fragment-Based Drug Discovery Agreement with Evotec - Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today that the Company and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a new drug discovery agreement targeting a protease chosen by Ono.
The collaboration applies Evotec’s proprietary fragment-based drug discovery platform, EVOlutionTM to identify novel, small molecular weight compounds active against a [...]
Evotec Expands Collaboration with InterMune - Hamburg, Germany | Oxford, UK- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that InterMune, Inc., has signed a second drug discovery contract with Evotec.
Evotec will support InterMune’s research efforts using their medicinal chemistry know-how. In addition, they will utilize their expertise and technologies in computational chemistry, protein production, X-Ray crystallography and ADMET to further [...]
Gossypol Biological Properties - Gossypol:
is a polyphenolic aldehyde that permeates cells and acts as an inhibitor for several dehydrogenase enzymes.
is antimalarial being the selective inhibitor of Plasmodium falciparum (pfLDH over hLDHs), an essential enzyme for energy generation within malarial parasite.
posesses proapoptotic properties, probably due to the regulation of the Bax and Bcl2.
reversibly inhibits Calcineurin and binds to calmodulin.
inhibits replication [...]
WUSTL creates center to study women’s infectious diseases - Washington University School of Medicine in St. Louis is launching a new effort to study infectious diseases that preferentially affect women. The center for Women’s Infectious Disease Research (cWIDR) will focus on issues such as:
• microorganisms that cause urinary tract infections (UTIs) and other conditions that make urination and intercourse painful or difficult
• infections that [...]
Amylin invests $10M in BioSeek - BioSeek, based in Burlingame, will work with San Diego-based Amylin (NASDAQ: AMLN) on treatments for inflammatory diseases. The work will put Amylin’s proprietary drug compounds through BioSeek’s biological screening systems to seek useful drugs. BioSeek can choose two peptide compounds after screening and develop them if it wishes, paying milestones and royalties to Amylin if [...]
New compounds promising candidates for neurodegenerative disease drug development - Scientists have developed a novel strategy for tackling neurodegenerative diseases such as Huntington’s disease: encouraging an individual’s own cells to “eat” the malformed proteins that lead to the disease.
Huntington’s disease is one of a number of degenerative diseases marked by clumps of malformed protein in brain cells. Symptoms include abnormal movements, psychiatric disturbances like depression [...]
Vastox Selects Preclinical Candidate In Duchenne Muscular Dystrophy Programme - VASTox plc (AIM: VOX), a leading UK biotechnology company, announces that it has selected a candidate to enter into preclinical development in the Company’s Duchenne Muscular Dystrophy (”DMD”) drug discovery programme.
VASTox has a unique therapeutic approach that targets the underlying cause of this disease. Owing to a genetic defect, DMD patients lack an important protein [...]
CALL FOR PAPERS: International Symposium on Advances in Synthetic and Medicinal Chemistry - The organisers cordially invite you to participate actively by submitting abstracts for poster and/or oral presentation in the upcoming second edition of ASMC 07 in St. Petersburg being prepared by EFMC (European Federation for Medicinal Chemistry) and ChemBridge Corporation with the support of ACSÂ and ACS Division of Medicinal Chemistry, in the [...]
International Symposium on Advances in Synthetic and Medicinal Chemistry - ASMC07 in St. Petersburg is being prepared by EFMC (European Federation for Medicinal Chemistry) and ChemBridge Corporation with the support of ACS and ACS Division of Medicinal Chemistry, in the series of events which started with ASCMC04 in Moscow.Out of the submitted abstract the Scientific Committee will chose 10
The scientific program of the International Symposium [...]
Advancing the Science of Drug Discovery: Bridging Research & Development - Society for Biomolecular Sciences
Presents its 13th Annual Conference & Exhibition
Advancing the Science of Drug Discovery: Bridging Research & Development
April 15-19, 2007
Palais Des Congres de Montréal
Montréal, Canada
After the Society’s most successful annual event in Seattle this year, professionals from around the globe will want to participate in the next SBS Annual Conference & Exhibition in April [...]
NCE Discovery and DARA BioSciences Join Forces to Develop New Therapies - CAMBRIDGE, England, Dec. 6, 2006–NCE Discovery Ltd (NCED), the specialist medicinal chemistry and drug design service provider, has entered into an agreement with US-based DARA BioSciences, Inc. to work together on the development of new drug target molecules.
DARA BioSciences discovers and develops small molecule treatments for metabolic and CNS diseases and, under the terms of [...]
Halozyme and Roche Enter Agreement for the Application of Enhanze, A Novel Technology to Improve Drug Delivery - BASEL, Switzerland and SAN DIEGO, Dec. 5 /PRNewswire/ — Halozyme Therapeutics, Inc. (AMEX:HTI) and Roche today announced they have entered into an agreement to apply Halozyme’s proprietary Enhanze(TM) Technology to Roche’s biological therapeutic compounds. Enhanze Technology is Halozyme’s proprietary drug delivery technology based on its recombinant human hyaluronidase (rHuPH20). rHuPH20 is an analogue of a [...]
Multiple Myeloma Research Foundation (MMRF) Awards $1 Million Each in Funding to ProChon Biotech and Semafore Pharmaceuticals to Advance Drug Development - NORWALK, Conn., Dec. 5 /PRNewswire/ — The Multiple Myeloma Research Foundation (MMRF), the largest non-profit foundation dedicated to accelerating a cure for multiple myeloma, today announced that Semafore Pharmaceuticals, Inc. and ProChon Biotech Ltd. are the recipients of the organization’s first LEAD (Leveraging Existing Multiple Myeloma Targets to Accelerate Drug Discovery and Development) research and [...]
Scientists Identify Synthetic Compound That Keeps Stem Cells Young - A team of scientists from the Scripps Research Institute, the Genomics Institute of the Novartis Research Foundation and the Max Planck Institute for Molecular Biomedicine has discovered a new synthetic compound that can support growth and self-renewal of mouse embryonic stem cells, offering a simple alternative to current growth conditions that may vary batch-to-batch and [...]
Setting The Stage To Find Drugs Against SARS - Scientists at the U.S. Department of Energy’s Brookhaven National Laboratory have set the stage for the rapid identification of compounds to fight against severe acquired respiratory syndrome (SARS), the atypical pneumonia responsible for about 800 deaths worldwide since first recognized in late 2002. Researchers from Brookhaven’s biology department and the National Synchrotron Light Source (NSLS) [...]
Definiens Enhances Drug Development Process - Definiens Cellenger: Flexible and Platform-independent Enterprise Solution Automates and Standardizes Cell Image Analysis Tailored to Specific Assays.
MUNICH, Germany and VIENNA, Austria - November 6, 2006 - Definiens AG, the number one Enterprise Image Intelligence solution provider, today introduced Definiens CellengerR v1.4. It is being announced at the High-Content Analysis Europe, November 6-8, Vienna, the most [...]
Evotec Discontinues EVT 301 Development Programme - HAMBURG, Germany and OXFORD, England, September 13 /PRNewswire-FirstCall/ — Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today reported that during the one month safety and tolerability study with EVT 301 in young and elderly volunteers, several cases of asymptomatic elevated liver function tests in the elderly group have been observed. All cases reversed spontaneously. [...]
Sensitive and Specific Biomarker for Early Detection of Prostate Cancer Identified - Newswise — Scientists at a Maryland-based pharmaceutical company have preliminary evidence showing that a protein in the blood may prove to be a biomarker that is more sensitive and specific than current methods of early detection for prostate cancer.
If they’re right, the protein – an enzyme called human aspartyl (asparaginyl) beta-hydroxylase, or HAAH – could [...]
Virtual screening services collaboration between Quantum Pharma and TimTec - Quantum Pharma, a drug discovery and computational chemistry software and contract services provider, Moscow, Russia, and TimTec, a provider of synthetic organic and natural compounds for bioscreening, Delaware, US, singed up a collaboration agreement. Quantum computational chemistry software with unique capabilities is available now through TimTec. In the future companies will co-develop products for drug-discovery [...]
Links
|
|
